Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis
SA Shah, S Sander, CM White, M Rinaldi… - The Lancet infectious …, 2007 - thelancet.com
Echinacea is one of the most commonly used herbal products, but controversy exists about
its benefit in the prevention and treatment of the common cold. Thus, we did a meta-analysis …
its benefit in the prevention and treatment of the common cold. Thus, we did a meta-analysis …
Myocarditis in patients treated with immune checkpoint inhibitors
…, MZO Hassan, JJ Moslehi, SP Shah… - Journal of the American …, 2018 - jacc.org
Background : Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint
inhibitors (ICI). Myocarditis after ICI has not been well characterized. Objectives : The …
inhibitors (ICI). Myocarditis after ICI has not been well characterized. Objectives : The …
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants
SS Shah - Cochrane Database of Systematic Reviews, 2020 - cochranelibrary.com
Background Patent ductus arteriosus (PDA) complicates the clinical course of preterm
infants and increases the risk of adverse outcomes. Indomethacin has been the standard …
infants and increases the risk of adverse outcomes. Indomethacin has been the standard …
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants
A Ohlsson, R Walia, SS Shah - Cochrane database of …, 2013 - cochranelibrary.com
Background Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA)
but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo‐…
but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo‐…
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants
A Ohlsson, R Walia, SS Shah - Cochrane Database of …, 2018 - cochranelibrary.com
Background Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA)
but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo‐…
but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo‐…
Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies
A Sharma, SR Shah, H Illum, J Dowell - Drugs, 2012 - Springer
Vemurafenib is the first molecularly targeted therapy to be licensed in the US and Europe
for treatment of advanced melanoma. Its mechanism of action involves selective inhibition of …
for treatment of advanced melanoma. Its mechanism of action involves selective inhibition of …
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants
MN Malviya, SS Shah - Cochrane Database of Systematic …, 2013 - cochranelibrary.com
Background A patent ductus arteriosus (PDA) with significant left to right shunt increases
morbidity and mortality in preterm infants. Early closure of the ductus arteriosus may be …
morbidity and mortality in preterm infants. Early closure of the ductus arteriosus may be …
Intricacies of bevacizumab-induced toxicities and their management
SM Gressett, SR Shah - Annals of Pharmacotherapy, 2009 - journals.sagepub.com
Objective: To review the serious and common toxicities of bevacizumab and describe their
incidence, risk factors, presentation, pathophysiology, and management. Data Sources: …
incidence, risk factors, presentation, pathophysiology, and management. Data Sources: …
Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis
…, RJ Sullivan, D Gupta, CP Mulligan, SP Shah… - Journal of the American …, 2020 - jacc.org
Background There is a need for improved methods for detection and risk stratification of
myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain (GLS) …
myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain (GLS) …
Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma
SV Keisner, SR Shah - Drugs, 2011 - Springer
Abstract Treatment options for renal cell carcinoma (RCC) have multiplied in the past 5 years.
Pazopanib is the third tyrosine kinase inhibitor (TKI) and the sixth targeted therapy that has …
Pazopanib is the third tyrosine kinase inhibitor (TKI) and the sixth targeted therapy that has …
